
OSTX Stock Forecast & Price Target
OSTX Analyst Ratings
Bulls say
OS Therapies is a clinical stage biopharmaceutical company targeting solid tumors with two promising drug technologies. The completion of the OST-HER2 clinical data package submission, multiple regulatory designations and strong biomarker support for potential accelerated FDA approval in 2026 should greatly increase investor confidence in the stock. The potential sale of a Priority Review Voucher valued at approximately $205M adds even more value to the company and could serve as a non-dilutive financing opportunity.
Bears say
OS Therapies is strategically shifting from clinical signal generation towards regulatory execution, with key catalysts such as completion of regulatory meetings in Q2 2026 and initiation of the global Phase 3 trial in Q3 2026, but faces significant risks as its pipeline is still in preclinical development and its potential PRV monetization may not materialize. Additionally, there is limited financial information available for the company, making it difficult to evaluate its overall financial health and potential for profitability.
This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.
OSTX Analyst Forecast & Price Prediction
Start investing in OSTX
Order type
Buy in
Order amount
Est. shares
0 shares